

## Special Issue

# 20th Anniversary of Pharmaceuticals—Met Receptor

### Message from the Guest Editors

Novel MET-targeted therapies have emerged as promising approaches in cancer treatment. One such approach involves the development of highly selective small-molecule inhibitors that specifically target the MET kinase domain, blocking its activity and downstream signaling pathways. Another innovative strategy utilizes engineered MET-targeted antibodies or bispecific antibodies that simultaneously target MET and another cancer-associated protein, enhancing the efficacy of MET inhibition and potentially overcoming resistance mechanisms. These novel therapies hold great potential for personalized cancer treatment and are being actively investigated in preclinical and clinical settings. This Special Issue invites submissions covering various aspects of recent research related to the newly discovered physiological and pathological functions and regulatory mechanisms of the MET proto-oncogene, as indicated previously.

### Guest Editors

Prof. Dr. Tiziana Crepaldi

Department of Oncology, Candiolo Cancer Institute, University of Turin,  
FPO-IRCCS, Candiolo, Italy

Dr. Simona Gallo

Department of Oncology, Candiolo Cancer Institute, University of Turin,  
FPO-IRCCS Strada Provinciale 142, 10060 Candiolo, Italy

### Deadline for manuscript submissions

closed (25 September 2024)



## Pharmaceuticals

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.8  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/si/179704](https://mdpi.com/si/179704)

*Pharmaceuticals*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)

[mdpi.com/journal/  
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





# Pharmaceuticals

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.8  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/journal/  
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



## About the Journal

### Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

---

### Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)